Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 8/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 8/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 7/20 | 0.35 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10126746 | 0.81 | MAPT (0.39) | MAPK1 | |
| SCHEMBL2132482 | 0.78 | MAP2K4 (0.43) | MAPK1CNR2FFAR1NR4A2RXRA | |
| SCHEMBL2132478 | 0.78 | MAP2K4 (0.43) | MAPK1CNR2FFAR1NR4A2RXRA | |
| SCHEMBL10154478 | 0.78 | SLC6A4 (0.38) | CNR2MAP2K1 | |
| SCHEMBL10126649 | 0.76 | APP (0.36) | APP | |
| SCHEMBL10154468 | 0.76 | KMT2A (0.38) | CNR2APP | |
| SCHEMBL3832735 | 0.73 | PDK2 (0.39) | — | |
| SCHEMBL21733021 | 0.72 | PDK2 (0.47) | MAPK1 | |
| SCHEMBL1666614 | 0.72 | FFAR1 (0.41) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL1666615 | 0.72 | FFAR1 (0.41) | FFAR1NR4A2RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412711-A1 | INDAZOLEPROPIONIC ACID AMIDE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20120016117-A1 | INDAZOLEPROPIONIC ACID AMIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016117-A1 | INDAZOLEPROPIONIC ACID AMIDE COMPOUND | SCN9A, SCN1A, SCN1B | MAPK1 269/4885CNR2 530/4885FFAR1 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.